Abeona Therapeutics Inc. Overview
Pro stress-test →Abeona Therapeutics is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. ZEVASKYN is the first and only autologous cell-based gene therapy for the treatment of adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company is transitioning from clinical to commercial stage with FDA approval and initial patient treatments underway.
Strategic Profile
Pro stress-test →The company anticipates normalizing patient treatment metrics by Q1 2026 and the introduction of a permanent product J-code by CMS in January 2026 is expected to support revenue growth. Abeona is strategically expanding its qualified treatment center network, with three activated centers including Children's Hospital Colorado. The company projects profitability in the first half of 2026.
Competitive Landscape
Pro stress-test →Abeona operates in the cell and gene therapy space competing with larger players like Bluebird Bio, Sangamo Therapeutics, and other rare disease therapeutics companies. The company's main competitive advantage is having the first and only FDA-approved autologous cell-based gene therapy for RDEB, creating a near-term market monopoly in this indication before potential competitors enter.
Industry Context
Abeona Therapeutics Inc. operates in Biopharmaceutical - Cell and Gene Therapy.
Key facts
Founded: 1974 · Headquarters: Cleveland, US · Revenue: $32M (2025E) · Market cap: $215M